It is a synthetic peptide with structural modifications that protect it from rapid degradation
Additionally, patient assistance programs may help reduce out-of-pocket costs
LY is a triple agonist that is currently being studied for its strong activity on the glucagon receptor, glucagon-like polypeptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) receptors
Because patients may receive GLP-1 prescriptions from primary care, endocrinology, or obesity medicine specialists, coordination with obstetrics and gynecology is essential
(12, 13) This review examined the extent to which GLP-1 receptor agonists modulate this metabolic environment, with preclinical and clinical studies presenting varying results
59.7 kDa immunoglobulin G4-fusion molecule), a shorter half-life (1115 hours vs